Ergomed Notice of Preliminary Results
Source: RNS
PRESS RELEASE
Notice of Preliminary Results
Guildford, UK - 28 February 2022: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its preliminary results for the year ending 31 December 2021 on Tuesday 29 March 2022.
Miroslav Reljanović, Executive Chairman, Richard Barfield, Chief Financial Officer, and Keith Byrne, Senior Vice-President, Capital Markets & Strategy, will host an in-person briefing for analysts at 9.30am GMT on the day of the results at the offices of Numis, 45 Gresham St, London EC2V 7BF. There will also be a live webcast and conference call with a Q&A session.
ENDS
Enquiries:
|
Ergomed plc |
Tel: +44 (0) 1483 402 975 |
|
Miroslav Reljanović (Executive Chairman) |
|
|
Richard Barfield (Chief Financial Officer) Keith Byrne (Senior Vice-President, Capital Markets & Strategy) |
|
|
|
|
|
Numis (Nominated Advisor and Joint Broker) |
Tel: +44 (0) 20 7260 1000 |
|
Freddie Barnfield / Euan Brown (Nominated Adviser) |
|
|
James Black (Broker) |
|
|
Peel Hunt LLP (Joint Broker) James Steel / Dr Christopher Golden |
Tel: +44 (0) 20 7418 8900
|
|
Consilium Strategic Communications - for UK enquiries |
Tel: +44 (0) 20 3709 5700 |
|
Chris Gardner / Matthew Neal |
|
|
Angela Gray |
|
|
|
|
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
